| scholarly article | Q13442814 |
| P50 | author | Kerry D Fisher | Q58227976 |
| P2093 | author name string | Leonard W Seymour | |
| Ratna Rajaratnam | |||
| Sarah Hale | |||
| Vivien Mautner | |||
| Mark Lyons | |||
| David Onion | |||
| Miriam Bazan-Peregrino | |||
| Kriss Aslan | |||
| Nicky K Green | |||
| Sue Phipps | |||
| P2860 | cites work | "Stealth" adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung | Q33841039 |
| Regulatory approvals of pediatric oncology drugs: previous experience and new initiatives | Q35085457 | ||
| Transductional and transcriptional targeting of adenovirus for clinical applications | Q35698621 | ||
| Heparan sulfate glycosaminoglycans are receptors sufficient to mediate the initial binding of adenovirus types 2 and 5. | Q39607095 | ||
| Upregulation of integrins alpha v beta 3 and alpha v beta 5 on human monocytes and T lymphocytes facilitates adenovirus-mediated gene delivery | Q39869620 | ||
| Neutralization of adenoviruses: kinetics, stoichiometry, and mechanisms | Q40128651 | ||
| Tumor cell targeted gene delivery by adenovirus 5 vectors carrying knobless fibers with antibody-binding domains. | Q40498926 | ||
| Effect of adenovirus serotype 5 fiber and penton modifications on in vivo tropism in rats | Q40528538 | ||
| Gene transduction and cell entry pathway of fiber-modified adenovirus type 5 vectors carrying novel endocytic peptide ligands selected on human tracheal glandular cells. | Q40545892 | ||
| An adenovirus vector with a chimeric fiber derived from canine adenovirus type 2 displays novel tropism | Q40548373 | ||
| Catheter-based intracoronary myocardial adenoviral gene delivery: importance of intraluminal seal and infusion flow rate. | Q40569551 | ||
| Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma | Q40586640 | ||
| Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity | Q40601029 | ||
| Adenovirus serotype 5 fiber shaft influences in vivo gene transfer in mice | Q40640134 | ||
| Deletion of penton RGD motifs affects the efficiency of both the internalization and the endosome escape of viral particles containing adenovirus serotype 5 or 35 fiber knobs | Q40722127 | ||
| Quantitation of adenovirus DNA and virus particles with the PicoGreen fluorescent Dye. | Q40922250 | ||
| Persistent infection of human adenovirus type 5 in human monocyte cell lines | Q41621283 | ||
| Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: intratumoral spread and distribution effects | Q41710263 | ||
| Retargeting of adenoviral infection to melanoma: Combining genetic ablation of native tropism with a recombinant bispecific single‐chain diabody (scDb) adapter that binds to fiber knob and HMWMAA | Q43501855 | ||
| Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. | Q43583253 | ||
| A minimally invasive approach for efficient gene delivery to rodent hearts | Q44737488 | ||
| The release of inflammatory cytokines from human peripheral blood mononuclear cells in vitro following exposure to adenovirus variants and capsid | Q45055906 | ||
| Virus-directed enzyme prodrug therapy: intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer | Q45658005 | ||
| PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. | Q45858804 | ||
| A phase I/II study of hepatic artery infusion with wtp53-CMV-Ad in metastatic malignant liver tumours | Q45861844 | ||
| Titer determination of Ad5 in blood: a cautionary note | Q45862533 | ||
| Extended plasma circulation time and decreased toxicity of polymer-coated adenovirus | Q45876214 | ||
| Prostate specific membrane antigen (PSMA) is a tissue-specific target for adenoviral transduction of prostate cancer in vitro | Q45878263 | ||
| Uptake of HIV and latex particles by fresh and cultured dendritic cells and monocytes | Q62129136 | ||
| P433 | issue | 1 | |
| P921 | main subject | Adenoviridae | Q193447 |
| P304 | page(s) | 118-128 | |
| P577 | publication date | 2006-03-31 | |
| P1433 | published in | Molecular Therapy | Q15762400 |
| P1476 | title | Adenovirus type 5 interactions with human blood cells may compromise systemic delivery | |
| P478 | volume | 14 |
| Q64377012 | A phase I trial of intravenous infusion of ONYX-015 and enbrel in solid tumor patients |
| Q34473301 | Active Adenoviral Vascular Penetration by Targeted Formation of Heterocellular Endothelial–epithelial Syncytia |
| Q42236177 | Activity of a group B oncolytic adenovirus (ColoAd1) in whole human blood. |
| Q99400790 | Ad5/3 is able to avoid neutralization by binding to erythrocytes and lymphocytes |
| Q36445557 | Ad5:Ad48 hexon hypervariable region substitutions lead to toxicity and increased inflammatory responses following intravenous delivery |
| Q36935134 | Adenoviral vectors for gene therapy |
| Q40526707 | Adenovirus coxsackie adenovirus receptor-mediated binding to human erythrocytes does not preclude systemic transduction |
| Q38957410 | Adenovirus sensing by the immune system |
| Q89606305 | Adenovirus-Antibody Complexes Contributed to Lethal Systemic Inflammation in a Gene Therapy Trial |
| Q41786777 | Adenovirus-platelet interaction in blood causes virus sequestration to the reticuloendothelial system of the liver |
| Q37859842 | Advances and future challenges in adenoviral vector pharmacology and targeting |
| Q45857526 | An ex vivo loop system models the toxicity and efficacy of PEGylated and unmodified adenovirus serotype 5 in whole human blood |
| Q38637597 | Angiogenic gene therapy for refractory angina |
| Q36723147 | Cell-based delivery of oncolytic viruses: a new strategic alliance for a biological strike against cancer |
| Q50977875 | Challenges and Prospects for Helper-Dependent Adenoviral Vector-Mediated Gene Therapy. |
| Q36276187 | Circumventing antivector immunity by using adenovirus-infected blood cells for repeated application of adenovirus-vectored vaccines: proof of concept in rhesus macaques |
| Q36463004 | Current advances and future challenges in Adenoviral vector biology and targeting |
| Q39995496 | Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity |
| Q26782083 | Development of Novel Adenoviral Vectors to Overcome Challenges Observed With HAdV-5-based Constructs |
| Q33286806 | Development of renal-targeted vectors through combined in vivo phage display and capsid engineering of adenoviral fibers from serotype 19p. |
| Q36868494 | Engineering targeted viral vectors for gene therapy |
| Q30446996 | Enhanced tumor uptake and penetration of virotherapy using polymer stealthing and focused ultrasound |
| Q45875328 | Factors influencing retention of adenovirus within tumours following direct intratumoural injection. |
| Q36649681 | Gene therapy targeting to tumor endothelium |
| Q40119187 | Gene-therapy delivery strategies in cardiology |
| Q37582126 | Helper-Dependent Adenoviral Vectors. |
| Q34982825 | Helper-dependent adenoviral vectors for liver-directed gene therapy. |
| Q41650213 | Human coagulation factor X-adenovirus type 5 complexes poorly stimulate an innate immune response in human mononuclear phagocytes |
| Q92423010 | Identification of folate receptor α (FRα) binding oligopeptides and their evaluation for targeted virotherapy applications |
| Q39946508 | In vitro and in vivo properties of adenovirus vectors with increased affinity to CD46 |
| Q45866594 | In vivo and in vitro distribution of type 5 and fiber-modified oncolytic adenoviruses in human blood compartments |
| Q41900381 | Influence of coagulation factor zymogens on the infectivity of adenoviruses pseudotyped with fibers from subgroup D. |
| Q37718852 | Innate immunity to adenovirus |
| Q37290953 | International progress in cancer gene therapy. |
| Q35557004 | Manipulating adenovirus hexon hypervariable loops dictates immune neutralisation and coagulation factor X-dependent cell interaction in vitro and in vivo |
| Q37984486 | Manipulation of adenovirus interactions with host factors for gene therapy applications |
| Q38081027 | Mechanistic, technical, and clinical perspectives in therapeutic stimulation of coronary collateral development by angiogenic growth factors |
| Q37310677 | Mesenchymal stem cells expressing TRAIL lead to tumour growth inhibition in an experimental lung cancer model |
| Q35360600 | Methods to improve cardiac gene therapy expression |
| Q60911893 | Microbubble-mediated delivery of human adenoviruses does not elicit innate and adaptive immunity response in an immunocompetent mouse model of prostate cancer |
| Q34697474 | Modification of adenovirus gene transfer vectors with synthetic polymers: a scientific review and technical guide |
| Q39725822 | Multi-component polymeric system for tumour cell-specific gene delivery using a universal bungarotoxin linker |
| Q30440788 | Myocardial gene transfer: routes and devices for regulation of transgene expression by modulation of cellular permeability |
| Q90481586 | Oligopeptide-modified poly(beta-amino ester)s-coated AdNuPARmE1A: Boosting the efficacy of intravenously administered therapeutic adenoviruses |
| Q33906116 | Oncolytic Viruses for Cancer Therapy: Overcoming the Obstacles |
| Q37845399 | Oncolytic vaccinia virus for the treatment of cancer |
| Q38924562 | Oncolytic virotherapy for head and neck cancer: current research and future developments |
| Q37300008 | Oncolytic viruses: a novel form of immunotherapy |
| Q37926486 | Oncolytic viruses: do they have a role in anti-cancer therapy? |
| Q26772039 | Oncolytic viruses: finally delivering |
| Q39673661 | Osteosarcoma cells as carriers to allow antitumor activity of canine oncolytic adenovirus in the presence of neutralizing antibodies |
| Q26769977 | Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade |
| Q39788723 | PEGylation of vesicular stomatitis virus extends virus persistence in blood circulation of passively immunized mice |
| Q41706961 | Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection. |
| Q33633287 | Preclinical Safety Studies of Enadenotucirev, a Chimeric Group B Human-Specific Oncolytic Adenovirus |
| Q37399961 | Preclinical evaluation of innate immunity to baculovirus gene therapy vectors in whole human blood |
| Q63246477 | Preexisting Virus-Specific T Lymphocytes-Mediated Enhancement of Adenovirus Infections to Human Blood CD14+ Cells |
| Q37089746 | Progress and prospects: gene therapy for genetic diseases with helper-dependent adenoviral vectors. |
| Q38950257 | Quantum dot labelling of adenovirus allows highly sensitive single cell flow and imaging cytometry |
| Q37330624 | Replacement of native adenovirus receptor-binding sites with a new attachment moiety diminishes hepatic tropism and enhances bioavailability in mice |
| Q64052778 | Skin immunisation activates an innate lymphoid cell-monocyte axis regulating CD8 effector recruitment to mucosal tissues |
| Q40740910 | Sustained, localized transgene expression mediated from lentivirus-loaded biodegradable polyester elastomers |
| Q21284969 | Systemic delivery of oncolytic viruses: hopes and hurdles |
| Q33320604 | Systemic vesicular stomatitis virus selectively destroys multifocal glioma and metastatic carcinoma in brain. |
| Q40117676 | Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow |
| Q34765825 | Targeting adenovirus gene delivery to activated tumour-associated vasculature via endothelial selectins |
| Q42152828 | Targeting of adenovirus serotype 5 (Ad5) and 5/47 pseudotyped vectors in vivo: fundamental involvement of coagulation factors and redundancy of CAR binding by Ad5. |
| Q27653315 | The Cell Adhesion Molecule “CAR” and Sialic Acid on Human Erythrocytes Influence Adenovirus In Vivo Biodistribution |
| Q36823688 | The influence of blood on in vivo adenovirus bio-distribution and transduction. |
| Q33655401 | The influence of innate and pre-existing immunity on adenovirus therapy |
| Q28539158 | Traceless bioresponsive shielding of adenovirus hexon with HPMA copolymers maintains transduction capacity in vitro and in vivo |
| Q38614156 | Tropism-modification strategies for targeted gene delivery using adenoviral vectors |
| Q33931576 | Use of adenoviral vectors to target chemotherapy to tumor vascular endothelial cells suppresses growth of breast cancer and melanoma |
| Q47549105 | Vaccine vectors based on Adenovirus 19a/64 exhibit broad cellular tropism and potently restimulate HCMV-specific T cell responses ex vivo |
| Q26741952 | Viral Vectors for Gene Therapy: Current State and Clinical Perspectives |
| Q37262766 | Viral vectors: from virology to transgene expression |
| Q37989391 | Virotherapy of neuroendocrine tumors |
Search more.